The correlation of serum level and gene polymorphisms of interleukin-33 in atopic dermatitis Iraqi patients
Main Article Content
Keywords
Single nucleotide polymorphism, IgE, Body mass index, alleles, Atopic eczema.
Abstract
Atopic dermatitis (AD), also known as atopic eczema, is a chronic relapsing inflammatory skin condition. Interleukins-33 (IL-33) are inflammatory cytokines that highly expressed in the keratinocytes of AD-suffering patients. This study aimed to investigate the correlation of the IL-33 serum levels and single nucleotide polymorphisms (SNP) of its gene in the rs10975519. This study includes 100 patients with atopic dermatitis (AD) and 80 healthy controls. The result indicate there was no significant difference when compared between the body mass index (BMI) of patient and control groups. In addition, there were non-significant increase in the concentration of eosinophil in AD patients, in comparison with controls (p<0.553). While result of the total Immunoglobulin E (tIgE) was showed a high significant increase in t-IgE in patients with AD compared with controls (p<0.001). The findings showed that serum level of IL-33 was highly increased in patients of AD in compared with controls with (p<0.001). Also, no significant variations of IL-33 serum levels (p-value = 0.01), with age, gender, BMI, IgE, eosinophilia and duration of disease. Only age showed a significant correlation with IL-33 among patients and controls (p<0.001). SNPs rs10975519 of IL-33 gene was also investigated, and the result indicates that the patients whose carry elevated frequencies of both codominant CT, TT, dominant (CT+TT) or allele T of rs10975519 SNP are more likely infected with AD with odd ratios (2.4, 3.7, 6.2 and 1.8, respectively) among patient and control groups. No significant differences were observed in serum levels of IL-33 with its related-SNPs (rs10975519).
References
2. V. Morgenstern et al., ‘Atopic diseases, allergic sensitization, and exposure to traffic-related air pollution in children’, Am J Respir Crit Care Med, vol. 177, no. 12, pp. 1331–1337, 2008.
3. G. Kiebert et al., ‘Atopic dermatitis is associated with a decrement in health‐related quality of life’, Int J Dermatol, vol. 41, no. 3, pp. 151–158, 2002.
4. M. S. Senra and A. Wollenberg, ‘Psychodermatological aspects of atopic dermatitis’, British journal of dermatology, vol. 170, pp. 38–43, 2014.
5. G. Moscato et al., ‘Gender and occupational allergy: report from the task force of the EAACI Environmental and Occupational Allergy Interest Group’, Allergy, vol. 75, no. 11, pp. 2753–2763, 2020.
6. F. Barrenäs et al., ‘Gender differences in inflammatory proteins and pathways in seasonal allergic rhinitis’, Cytokine, vol. 42, no. 3, pp. 325–329, 2008.
7. E. Guttman-Yassky and J. G. Krueger, ‘Atopic dermatitis and psoriasis: two different immunediseases or one spectrum?’, Curr Opin Immunol, vol. 48, pp. 68–73, 2017.
8. F. Cipriani, A. Marzatico, and G. Ricci, ‘Autoimmune diseases involving skin and intestinal mucosa are more frequent in adolescents and young adults suffering from atopic dermatitis’, J Dermatol, vol. 44, no. 12, pp. 1341–1348, 2017.
9. X.-P. Hu et al., ‘Association of Fcγ receptor IIB polymorphism with cryptococcal meningitis in HIV-uninfected Chinese patients’, 2012.
10. L.-P. Boulet, H. K. Reddel, E. Bateman, S. Pedersen, J. M. FitzGerald, and P. M. O’Byrne, ‘The global initiative for asthma (GINA): 25 years later’, European Respiratory Journal, vol. 54, no. 2, 2019.
11. M. Prentice and S. A. Jebb, ‘Beyond body mass index’, Obesity reviews, vol. 2, no. 3, pp. 141–147, 2001.
12. Dei‐Cas, P. Dei‐Cas, and K. Acuña, ‘Atopic dermatitis and risk factors in poor children from Great Buenos Aires, Argentina’, Clinical and Experimental Dermatology: Clinical dermatology, vol. 34, no. 3, pp. 299–303, 2009.
13. J.-Y. Lee et al., ‘Exposure to gene-environment interactions before 1 year of age may favor the development of atopic dermatitis’, Int Arch Allergy Immunol, vol. 157, no. 4, pp. 363–371, 2012.
14. G. Muscogiuri et al., ‘Obesity in Prader–Willi syndrome: Physiopathological mechanisms, nutritional and pharmacological approaches’, J Endocrinol Invest, vol. 44, no. 10, pp. 2057–2070, 2021.
15. Z. Ali, C. S. Ulrik, T. Agner, and S. F. Thomsen, ‘Association between atopic dermatitis and the metabolic syndrome: a systematic review’, Dermatology, vol. 234, no. 3–4, pp. 79–85, 2018.
16. Navinés-Ferrer, E. Serrano-Candelas, G.-J. Molina-Molina, and M. Martín, ‘IgE-related chronic diseases and anti-IgE-based treatments’, J Immunol Res, vol. 2016, 2016.
17. M. M. S. Tayeb and M. M. Qutub, ‘Predictive accuracy of total IgE in detection of inhalant allergens sensitization’, J Fam Med Health Care, vol. 2, pp. 6–9, 2016.
18. S. T. Holgate, ‘Pathogenesis of asthma’, Clinical & Experimental Allergy, vol. 38, no. 6, pp. 872–897, 2008.
19. S. S. Possa, E. A. Leick, C. M. Prado, M. A. Martins, and I. F. L. C. Tibério, ‘Eosinophilic inflammation in allergic asthma’, Front Pharmacol, vol. 4, p. 46, 2013.
20. N. Nakamura et al., ‘Stratum corneum interleukin-33 expressions correlate with the degree of lichenification and pruritus in atopic
dermatitis lesions’, Clin Immunol, vol. 201, pp. 1–3, 2019.
21. Y. Imai et al., ‘IL-33–induced atopic dermatitis–like inflammation in mice is mediated by group 2 innate lymphoid cells in concert with basophils’, Journal of Investigative Dermatology, vol. 139, no. 10, pp. 2185–2194, 2019.
22. N. Siti, S. M. A. Noor, and A. R. Azriani, ‘Determination of serum interleukin 33 (IL-33) levels in atopic asthma patients using ELISA kits’, Journal of Fundamental and Applied Sciences, vol. 9, no. 6S, pp. 926–943, 2017.
23. P. N. Pushparaj et al., ‘The cytokine interleukin33 mediates anaphylactic shock’, Proceedings of the National Academy of Sciences, vol. 106, no. 24, pp. 9773–9778, 2009.
24. B. Basnet, S. Neupane, and S. Shrestha, ‘Serum IgE levels and severity of atopic dermatitis’, Journal of Universal College of Medical Sciences, vol. 3, no. 3, pp. 22–26, 2015.
25. M. K. Kägi, H. Joller-Jemelka, and B. Wüthrich, ‘Correlation of eosinophils, eosinophil cationic protein and soluble lnterleukin-2 receptor with the clinical activity of atopic dermatitis’, Dermatology, vol. 185, no. 2, pp. 88–92, 1992.
26. S. J. Arbes Jr, P. J. Gergen, L. Elliott, and D. C. Zeldin, ‘Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey’, Journal of Allergy and Clinical Immunology, vol. 116, no. 2, pp. 377–383, 2005.
27. D. A. Holmes, J. Yeh, D. Yan, M. Xu, and A. C. Chan, ‘Dusp5 negatively regulates IL‐33‐mediated eosinophil survival and function’, EMBO J, vol. 34, no. 2, pp. 218–235, 2015.
28. M. R. Silver, A. Margulis, N. Wood, S. J. Goldman, M. Kasaian, and D. Chaudhary, ‘IL-33 synergizes with IgE-dependent and IgEindependent agents to promote mast cell and basophil activation’, Inflammation research, vol. 59, no. 3, pp. 207–218, 2010.
29. M. Shimizu et al., ‘Functional SNPs in the distal promoter of the ST2 gene are associated with atopic dermatitis’, Hum Mol Genet, vol. 14, no. 19, pp. 2919–2927, 2005.
30. Zaryczańska, J. Gleń, M. Zabłotna, R. Nowicki, and M. Trzeciak, ‘Serum levels and single nucleotide polymorphisms of the interleukin-33 gene in atopic dermatitis’, Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, vol. 39, no. 1, 2022.
31. J. Coyle et al., ‘Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2–mediated lung mucosal immune responses’, J Exp Med, vol. 190, no. 7, pp. 895–902, 1999.
32. M. Sakashita et al., ‘Association of serum interleukin‐33 level and the interleukin‐33 genetic variant with Japanese cedar pollinosis’, Clinical & Experimental Allergy, vol. 38, no. 12, pp. 1875–1881, 2008.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.